NICE recommend venetoclax and azacytidine for patients with aggressive blood cancer

Venetoclax is an oral once-daily treatment, which blocks the action of the B-cell lymphoma-2 protein, the presence of which helps cancer cells survive. - News - PharmaTimes

Related Keywords

United Kingdom ,Charlie Craddock ,University Of Birmingham ,Centre For Clinical Haematology ,Final Appraisal Document ,Clinical Haematology ,Queen Elizabeth Hospital , ,